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AbstrACt
Patients with cancer who developed severe, grade 3 
or 4 immune- related adverse events (irAEs) during 
therapy with immune checkpoint inhibitors are at risk for 
developing severe toxicities again on rechallenge with 
checkpoint inhibitors. Consequently, medical oncologists 
and multidisciplinary teams are hesitant to retreat in this 
scenario, despite the fact that a number of patients may 
derive clinical benefit from this approach. Balancing such 
clinical benefit and treatment- related toxicities for each 
patient is becoming increasingly challenging as more 
and more patients with cancer are being treated with 
checkpoint inhibitors. In this manuscript, we provide an 
extensive overview of the relevant literature on retreatment 
after toxicity, and suggest prophylactic approaches to 
minimize the risk of severe irAE following rechallenge with 
immune checkpoint blockade, since treatment may be 
lifesaving in a number of occasions.
IntroduCtIon
The number of patients with cancer who 
receive immune checkpoint- based therapies 
is rapidly increasing following a growing 
number of approved indications. Further-
more, these treatments are moving from 
later line therapies to front- line therapies in 
the metastatic setting, as well as entering the 
early- disease neoadjuvant and adjuvant field. 
Highly interesting results are emerging from 
immune checkpoint inhibition (ICI) in the 
neoadjuvant trials,1–4 as well as using combi-
nation strategies, for example, anti- CTLA-4 
and anti- PD- (L)1, ICI plus other immune- 
based therapies, chemotherapy, radiation, 
antibody drug conjugates and targeted 
therapies. Parallel to this rise in number of 
patients treated with ICI, the number of 
patients developing immune- related adverse 
events (irAEs) is increasing.5 The incidence 
of severe toxicities differs depending on the 
agent administered, the dose, interval and 
duration of therapy. In descending order of 
risk, the highest risk of toxicity is seen with 
the combination of ipilimumab (anti- CTLA4) 
plus nivolumab (anti- PD-1) in metastatic 
melanoma, as in this disease patients are 
given high- dose ipilimumab (3 mg/kg) plus 
low- dose nivolumab (1 mg/kg) in melanoma 
and SCLC, low- dose ipilimumab of 1 mg/kg 
every 3 or 6 weeks plus nivolumab 3 mg/kg in 
renal cell carcinoma and non- small- cell lung 
carcinoma (NSCLC), or single- agent ipilim-
umab (3 mg/kg) in metastatic melanoma, or 
monotherapy anti- PD-1 or anti- PD- L1 agents 
in many indications.
These differences are also reflected by the 
discontinuation rate due to grade 3–4 irAEs 
(table 1). Most of these data are emerging 
from randomized controlled clinical trials, 
and may underestimate the discontinua-
tion rate in ‘real- world’ setting. Importantly, 
centers participating in clinical trials with ICI 
are often more experienced in irAEs recogni-
tion and management.
In clinical trials, patients who develop 
severe toxicities on ICI- based therapies are 
usually not allowed to resume ICI once their 
disease progresses, because of the chance of 
developing severe irAEs on rechallenge with 
immunotherapies (majority with anti- PD- (L)
one backbone combinations). Furthermore, 
a number of oncology teams may be hesitant 
to retreat patients or reinitiate ICI treatment 
even when the severe irAEs is under control 
and the immunosuppression is tapered off. 
This also depends on the type and grade of 
irAEs and how patients responded to the 
immunosuppressive treatment, and whether 
the patient is still on immunosuppressive 
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Table 1 The rate of permanent discontinuation of different 
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ICI, immune checkpoint inhibition.
therapy to control the irAEs, as well as the availability of 
alternative therapy options. Another important element 
has recently been reported concerning the initial 
response to ICI before the onset of an irAEs. The efficacy 
in patients with NSCLC who had an objective response 
prior to the onset of an irAE was similar in the retreatment 
cohort and discontinuation cohort, thus, these patients 
may not benefit from ICI rechallenge. Nevertheless, 
among patients without objective response at the time of 
the first serious irAE, progression- free survival and overall 
survival (OS) were improved on retreatment compared 
with those in whom treatment remained discontinued.6 
The major limitation of this study was the limited number 
of patients (n=38).
Unfortunately, most risk- versus- benefit factors contrib-
uting to rechallenge decision are unknown, which makes 
the choice to restart (or not) immunotherapy very 
challenging.
In case of grade 4 cardiovascular or neurological/
muscular irAEs, or severe pneumonitis requiring admis-
sion to the intensive care unit, associated with a high 
mortality rate, we assume that the fear of both the 
oncology team and the patient to induce the same or 
more severe irAEs on retreatment is high. Moreover, for 
patients who require escalation of immunosuppression 
to two or more drugs (eg, high- dose corticosteroids (CS) 
plus either mycophenolate mofetil, tacrolimus or antithy-
mocyte globulin (ATG)) to control the irAEs, we think 
the threshold to rechallenge with ICI will obviously get 
higher.
Thus, to choose between a potential effective treatment 
for a lethal cancer and Hippocrates ‘adagium’: ‘primum 
non- nocere’ (first, do no harm), can be very difficult. 
However, in order to make such clinical decisions, gran-
ular knowledge and careful balance of benefits and 
risks in a particular setting is needed. Here, we provide 
an overview of what is known in the literature and how 
we could use this knowledge to consider taking a calcu-
lated/balanced risk to possibly rechallenge a patient who 
recovered from severe irAEs with ICI- based therapy on a 
case by case basis. We propose a framework for a prophy-
lactic immunosuppressive approach to minimize the risk 
of severe toxicities on retreatment and to more safely 
reintroduce ICI. Such decision should be systematically 
discussed and validated in the context of multidisciplinary 
team meeting according to each patient risk:benefit ratio 
and unique circumstances. These recommendations are 
based on experts’ opinion. However, randomized clinical 
trials are needed to establish evidence- based guidelines 
forming the basis and criteria for ICI rechallenge in the 
future.
safety of retreatment with ICI after irAE resolution
We see three scenarios in which reintroducing ICI is 
possible after development of severe irAEs: first, to opt for 
a class switch from anti- PD- (L)1 to anti- CTLA-4 therapy 
or vice versa in diseases where both classes are clinically 
relevant; second, the rechallenge scenario with the rein-
troduction of the same class agent or the same molecule 
(ICI resumption) after (near) resolution of the irAE; 
and third, a secondary prevention scenario where ICI is 
resumed concomitantly with immunosuppressive therapy 
(table 2).
Class switch
So far, the only two classes of ICI in routine clinical use 
are anti- CTLA-4 and anti- PD- (L)1. Anti- CTLA-4 works by 
increasing the diversity of the antitumor immune response 
and perhaps by depleting highly CTLA-4 expressing Tregs 
from the tumor microenvironment, whereas PD-1/PD- L1 
blockade mostly works at the tumor site by locally re- acti-
vating a suppressed immune response. Because of these 
non- overlapping mechanisms of action, sequencing from 
one class to another may be feasible and beneficial for 
patients.
For the switch scenario, a retrospective analysis7 of 67 
patients with metastatic melanoma evaluated the safety of 
anti- PD-1 in the setting of prior severe irAEs with ipilim-
umab. In this cohort, most patients experienced severe 
toxicity with ipilimumab (76% grade 3, 10% grade 4), 
including 42 (63%) patients with grade 3/4 colitis (15 
were treated with infliximab), 3 (5%) with grade 3/4 
hepatitis (one of which required ATG) and 12 (18%) 
with hypophysitis. All irAEs, except hypophysitis, had 
been resolved at the time of initiation of anti- PD-1. Inter-
estingly, only two (3%) patients had recurrence of the 
same irAEs with anti- PD-1 therapy. Twenty- three (34%) 
patients developed new/different irAEs with anti- PD-1 
therapy. Fourteen (21%) patients had grade 3–4 irAEs, 
and eight (12%) discontinued therapy due to the devel-
opment of grade 3/4 pneumonitis (n=4), hepatitis (n=2), 
colitis (n=1) and myasthenia gravis (n=1). There were no 
treatment- related deaths. Of note, of the 12 patients with 
ipilimumab- induced hypophysitis, only one developed 
an irAEs, which was grade 3 colitis that was managed 
successfully with oral prednisone. With lack of prospec-
tive data, this retrospective study may suggest that the 
switch from anti- CTLA-4 to anti- PD-1 in patients with 
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previous anti- CTLA-4- related severe irAEs may be feasible 
in a number of patients. Another retrospective study8 
assessed the safety and toxicity of ipilimumab following 
failure of anti- PD-1 therapy in 40 patients with metastatic 
melanoma (assessment of all patients after progression 
on anti- PD-1 therapy and not only those with high- grade 
irAEs). Initially 8% of patients developed grade 3/4 
irAEs attributable to the PD-1 inhibitor. Globally, 35% of 
patients receiving ipilimumab after anti- PD-1 developed 
grade 3/4 irAEs. In this cohort, diarrhea or colitis was 
the most common high- grade irAEs (23%) with earlier 
onset, followed by hepatitis, pneumonitis and a case of 
encephalitis. In this cohort, three patients experienced 
grade 3/5 pneumonitis, and one patient died due to 
this treatment complication. Importantly, pneumonitis 
has rarely been described with ipilimumab therapy and 
is more commonly reported with PD-1 inhibitors. Two of 
the 14 (14%) patients who experienced high- grade irAEs 
with ipilimumab had developed severe irAEs (hypothy-
roidism, bullous pemphigoid) with previous anti- PD-1 
therapy. Even with this seemingly increased frequency 
of high- grade ICI- related pneumonitis, we consider that 
the switch from anti- PD-1 to anti- CTLA4 therapy or from 
anti- CTLA4 to anti- PD-1 therapy may be considered, espe-
cially by an experienced team and in the absence of other 
available treatment options, and could be manageable in 
a number of cases.
The only prospective data available came from the 
CheckMate-064 study,9 in which patients with metastatic 
melanoma were randomized to receive either ipilim-
umab (four courses), followed by nivolumab (6 courses 
at 2- week intervals), or nivolumab followed by ipilim-
umab. Patients were evaluated at the end of second 
treatment at week 25. At that time point, there was not 
a significant difference in grade 3–4 irAEs between arms 
(50% in nivolumab >ipilimumab vs 43% in ipilimumab 
>nivolumab). However, as expected, more patients devel-
oped grade 3–4 irAEs during the first induction treat-
ment in the ipilimumab >nivolumab arm (23%) vs 7% 
in patients receiving nivolumab during the first induc-
tion period. This was opposite in the second induction 
period with more grade 3–4 irAEs in the nivolumab 
>ipilimumab- treated patients (52% vs 28%). The most 
important reason to discontinue treatment was different 
between the two arms; toxicity versus disease progression 
were 34% and 26% for the nivolumab >ipilimumab arm 
and 17% and 56% for the ipilimumab >nivolumab- treated 
patients, indicating that sequencing of ICI classes impacts 
on the discontinuation rate due to irAEs. All patients who 
started the first treatment, also initiated the second treat-
ment. About 50% then went to maintenance nivolumab 
(both arms) after week 25, illustrating the feasibility of 
sequencing these drugs.
Importantly, when considering the sequencing from 
one class of ICI to another, the relatively long half- life 
of the agents and the duration of receptor occupancy 
of peripheral blood T cells, which can last for up to 
2 months, can be important considerations. Therefore, 
on switching from one drug class to another within 
this period of receptor occupancy, may be equivalent 
to giving these agents combined with a possibly higher 
chance of inducing irAEs. Toxicity data from randomized 
controlled trials in patients treated with combination ICI 
upfront compared with sequential treatment is, however, 
not available.
re-challenge
Another study10 of 80 patients retrospectively evaluated 
the safety of resuming anti- PD-1 monotherapy in patients 
with severe toxicity from ICI combination therapy 
leading initially to discontinuation. In this cohort, the 
patients discontinued combination therapy due to irAEs, 
including colitis (41%), hepatitis (36%) and pneumonitis 
(4%). The highest grade of irAE experienced with combi-
nation therapy was grade 2 in 25 (31%) patients, grade 
3 in 49 (61%) and grade 4 in 6 (8%) patients. Among 
these patients, 77 (96%) received CS and 21% received 
additional immunosuppression (eg, infliximab). All 
patients were rechallenged with anti- PD-1 and 40 (50%) 
patients experienced any grade irAEs. Of these patients, 
26 (33%) had grade 1–2 events, and 14 (18%) had grade 
3–5 toxicities; 24 (30%) patients discontinued anti- PD-1 
due to these events; only 14 (18%) had recurrent irAEs. 
Patients with neurological toxicity (n=2), uveitis (n=2) 
and ITP (n=1) did not experience recurrence. On the 
contrary, hepatitis (5 recurrences out of 29 patients, 
17%), pancreatitis (2 of 2, 100%), pneumonitis (1 of 
3, 33%) and nephritis (1 of 2, 50%) appeared to recur 
more often. Only one fatal Stevens- Johnson syndrome 
occurred after monotherapy rechallenge. Importantly, 
many of these toxicities were not confirmed by patholog-
ical examination of organ biopsies (or bronchoalveolar 
lavage (BAL) in case of pneumonitis), not excluding the 
potential for other causes of liver test abnormalities and 
creatinine elevation. Interestingly, colitis was less likely to 
recur compared with other irAEs (6% vs 28%). Clinically 
significant but distinct toxicities occurred in additional 
17 (21%) patients (11 grade 1–2 and 6 grade 3–4). Ten 
of the 14 patients (71%) discontinued anti- PD-1 therapy 
due to these recurrent irAEs, but in this relatively small 
series no other fatal events occurred. In total, 39% (n=31) 
of patients experienced clinically significant recurrent 
or distinct toxicities. Notably, the duration of steroid 
tapering, severity of initial irAEs and use of additional 
immunosuppressants did not predict toxicity on rechal-
lenge in this retrospective analysis, although patients 
remaining on steroid therapy at the time of anti- PD-1 
resumption had higher toxicity rates (55% vs 31%). We 
noted a relatively high rate (21%) of clinically signifi-
cant but distinct irAEs on anti- PD-1 rechallenge that is 
higher than that the incidence noted with conventional 
single- agent anti- PD-1 therapy. In this study, the type of 
toxicity appeared to be informative. Very few patients with 
‘ipilimumab- like’ toxicities, including colitis and hypoph-
ysitis, experienced recurrence with anti- PD-1 in contrast 
to ‘anti- PD-1- like’ toxicities, such as hepatitis, nephritis, 
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pancreatitis and pneumonitis, which appeared to have 
higher risk of recurrence. Based on this small study, it 
can be considered that patients with previous ICI- related 
colitis or hypophysitis may potentially resume anti- PD-1 
treatment after careful evaluation and discussion.
For the rechallenge scenario with the same agent class, 
a cohort6 of 38 patients with NSCLC who had experienced 
irAEs (34% grade3-4) with anti- PD- (L)1 (nivolumab, 
pembrolizumab, atezolizumab or durvalumab), either 
as monotherapy or in combination with anti- CTLA-4 
therapy (ipilimumab or tremelimumab), were retreated 
with anti- PD- (L)1 after irAE resolution or improvement 
to grade 1. In this study, after retreatment, 18 (48%) 
patients had no subsequent irAEs, 10 (26%) experienced 
recurrence of the initial irAE and 10 (26%) had a new 
irAE. Most recurrent/new irAEs were mild (58%) grade 
1–2) and manageable (84% resolved or improved to 
grade 1). The rate of recurrent/new irAEs was compa-
rable among patients who initially had grade 1/2 or grade 
3/4 events (12 of 25 (48%) vs 8 of 13 (61%)). Recurrent/
new irAEs were more common among those requiring 
hospitalization for the initial irAEs (7 of 8 (87%) vs 13 
of 30 (43%)). No evident trends in differential rates of 
new/recurrent irAEs based on the type of initial irAE 
were observed, except for higher frequency of recurrent/
new irAEs in patients who initially had arthralgia/myalgia 
(4 of 6, 67%). Most recurrent/new irAEs in the retreat-
ment cohort were mild (12 (60%) grade 1–2; 8 (40%) 
grades 3–4) and were manageable (17 (85%) resolved 
or improved to grade 1). Two treatment- related deaths 
occurred. Apart from the small size of the cohort, and 
the retrospective design of the study, another important 
limitation of this cohort was the absence of available 
information on the exact ICI used for the rechallenge. 
In summary, based on the limited available literature, we 
may consider rechallenge with ICI following temporary 
discontinuation because of grade 3–4 irAEs on prior ICI 
treatment, to be feasible in the majority of patients. We 
may expect new and/or recurrent toxicities to occur, the 
majority of which can be manageable, especially when 
given in centers with ample multi- disciplinary experience 
in irAEs management.
For ICI resumption, two recent studies revealed the 
feasibility of resuming ICI in patients who discontinue 
treatment due to irAEs. The first is a cohort11 of 93 patients 
who experienced ≥grade 2 irAEs after anti- PD- (L)1 had an 
anti- PD- (L)1 rechallenge. In this cohort, the initial irAEs 
rates were 46% grade 2, 39% grade 3% and 15% grade 4 
events. In that study, 49 patients (53%) had been treated 
with steroids, and 7 patients (7.5%) required disease 
modifying or other immunosuppressive agents. Forty 
(43%) of the 93 patients were rechallenged with the same 
ICI. Eighteen patients (45%) did not experience further 
irAEs. However, 17 patients (42.5%) experienced recur-
rence of the same type of irAE, and 5 patients (12.5%) 
experienced a different irAE. Importantly, the frequency 
of recurrence irAEs differed: five out of six patients for 
arthralgia, two out of three for grade 4 neutropenia, three 
out of five for colitis, three out of five for hepatitis, three 
out of seven for skin irAEs, one out of five for pneumo-
nitis and none of three for lipase elevation. The severity 
distribution for the second irAE was 38% for grade 2, 
48% for grade 3 and 14% for grade 4. The second irAEs 
were not more severe than the initial event. The second 
publication reported a study12 that evaluated 167 patients 
with ICI- related immune- mediated diarrhea and colitis 
(IMDC) recurrence after ICI resumption (the majority 
with the same class). Initial ICI therapy was PD- (L)1 
inhibitor in 47% of patients, CTLA-4 inhibitor in 28% or 
a combination in 25% of patients. Seventy- five patients 
had an endoscopic evaluation, meaning that in 25% of 
patients the diagnosis IMDC and severity thereof (ulcer-
ation, extent of colon affected) was not present. Most 
patients who developed IMDC required immunosuppres-
sion with CS (113; 68%); among them, 24 patients (14%) 
required treatment escalation to addition of infliximab or 
vedolizumab (VDZ). Non- gastrointestinal (GI) irAEs were 
reported in 72 patients (43%) and involved skin (n=22), 
liver (n=11), endocrine organs (n=29), lung (n=9) or 
other sites (n=19). Of the 167 patients in this cohort, 32 
resumed CTLA-4 therapy, and 135 resumed anti- PD- (L)1 
therapy. IMDC recurred in 57 patients (34%), with 44% 
on anti- CTLA-4% and 32% on anti- PD- (L)1; additionally, 
47 of those patients (82%) required immunosuppressive 
therapy, and all required permanent discontinuation of 
ICI. Most patients (70%) developed grade 2 diarrhea, 
with 54% experiencing grade 1 colitis, and there was no 
irAE- related mortality.
Based on these case series, we have reason to believe 
that the IMDC severity after restarting ICI treatment can 
be manageable, and recurrence maybe less frequent after 
resumption of anti- PD- (L)1.
In making a decision on resuming the ICI, we have to 
take the original IMDC severity in careful consideration, 
as this will be different for patients with grade 4 IMDC 
requiring more than one drug to manage the colitis, 
compared with patients with mild colitis, which is more 
often the case with anti- PD- (L)1. Curiously, multivari-
able analysis in a study by Wang and team showed that 
patients treated with initial anti- CTLA-4 were significantly 
less likely to develop recurrent IMDC on rechallenge 
than those treated with anti- PD- (L)1 treatment first. In 
contrast, the risk for IMDC recurrence in this study was 
significantly lower when PD- (L)1 rather than CTLA-4 
inhibitors were used for ICI resumption. That study also 
reported a significantly increased risk for IMDC recur-
rence with longer duration of IMDC symptoms and use 
of immunosuppressive therapy in the initial episode, 
associations that were also identified by Lambotte et 
al13, although without reaching statistical significance. 
The only factor significantly and independently linked 
with irAE recurrence in the Lambotte et al study was the 
time between treatment initiation and the first irAE: 
patients who did versus did not experience recurrence 
had a shorter such median interval at 9 and 15 weeks, 
respectively.
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rechallenge with concurrent immunosuppression?
For the third scenario, available data are still very limited, 
but interesting reports have been published. In a study 
with 14 patients with initial severe ICI- related colitis, 
ICI was resumed after IMDC resolution. Eight patients 
received VDZ concurrently with ICI infusions, and six did 
not. Interestingly, after ICI resumption, the rate of IMDC 
recurrence with VDZ was significantly lower compared 
with that in patients without VDZ (12.5% vs 50%, respec-
tively). Additionally, this rate obtained with secondary 
prevention was significantly lower than the rate reported 
previously in other studies without prevention estimated 
at approximately 35%–40%.14 Another small study evalu-
ated the concurrent therapy with ICI and tumor necrosis 
factor α (TNFα) blockade in patients with GI irAEs. All 
five patients tolerated further ICI with no recurrence 
of symptoms and repeat endoscopies showed resolution 
of acute inflammation and restaging imaging showed 
no cancer progression.15 Another retrospective study 
found that the use of prophylactic budesonide in patients 
with only microscopic colitis without visible endoscopic 
inflammation to be effective in allowing concomitant ICI 
therapy.16
Although no firm conclusions can be drawn from these 
three small studies, VZB clearly has activity in IMDC. Espe-
cially in the light of the recently published ‘real- world’ 
data on the potential decrease in survival of patients 
receiving infliximab as escalated immunosuppression for 
severe irAEs (especially IMDC),17 VZB maybe a reason-
able alternative. However, given the underlying mecha-
nism of action, potential negative impact from VZB in 
cancer response and outcome especially in patients with 
primary GI malignancy and GI involvement of distal 
metastasis from other primary cancers still requires 
further elucidation.
Moreover, OS analysis indicated no negative impact for 
VDZ adjunction.18 Another patient with metastatic mela-
noma and prior serious ICI- related arthritis and colitis 
received ipilimumab while remaining on tocilizumab 
TCZ. After 3 months of concomitant therapy with TCZ 
and ipilimumab, the patient’s joint symptoms improved, 
and no symptoms of colitis/diarrhea were reported, 
despite being off budesonide.19 The concurrent intro-
duction of selective immunosuppressants SIs such as VDZ 
or TCZ merit further investigation in prospective clinical 
trials as secondary prevention after ICI resumption in 
patients with previous severe irAEs to assess both onco-
logical and irAE outcomes.
A conclusion from all these studies is the absence of reli-
able predictive and prognostic factors for severe recurrent 
or distinct irAEs after ICI readministration. Moreover, 
the risk factors are not clearly understood and are vari-
able and inconsistent across studies. The small number 
of patients on which these studies are based, limited our 
ability to draw any formal conclusions and recommenda-
tions in terms of ICI rechallenge and secondary preven-
tion strategies. However, in a number of patients with 
severe initial irAEs, ICI resumption could be considered, 
especially in the absence of therapeutic alternatives. 
However, in such cases, treatment decisions should be 
made based on an interdisciplinary expertize basis, also 
taking into account irAE type, grade and timing, response 
to immunosuppression, life expectancy, performance 
status, comorbid conditions, patient preferences, other 
available cancer therapy options, among other factors. In 
routine practice, ICI permanent discontinuation is often 
selected in patients with severe irAEs. We further advo-
cate that great caution is needed regarding rechallenge. 
Actually, rechallenge should ideally be attempted with 
single agent ICI, only in patients with not life threatening, 
immunosuppression- sensitive and ideally resolved (or at 
least well controlled) initial irAEs. In contrast, occurrence 
of severe cardiovascular, neurological/muscular or other 
really threatening irAEs should raise even higher concern 
regarding ICI reexposure. Before ICI resumption, we 
highly advise for a personalized baseline assessment as 
proposed by Martins et al20 according to the risk profile of 
each patient, ideally by a multispecialty team in an expe-
rienced center. After potential ICI resumption, we advise 
very close monitoring for progression, prompt recogni-
tion and management of recurrent/distinct irAEs, as well 
as prompt ICI discontinuation as clinically indicated.
suggested approach to ICI rechallenge
The correlation between irAEs and treatment response 
has been consistently reported for different cancer types21 
such as melanoma,22–24 lung cancer25–28 or urothelial carci-
noma29; although few reports oppose such association.30 
Importantly, one flaw with these studies is that patients 
developing irAEs may have received longer ICI treatment 
as patients with rapid disease progression may not have 
had the time to develop irAEs. Therefore, selection and 
confounding biases may have been introduced, and thus 
these results should be interpreted cautiously. The ICI 
resumption treatment after high- grade irAEs is always a 
challenging decision because of the potential severity of 
the irAE recurrence and the absence of formal guidelines. 
Given the reports of benefit from ICI resuming treatment 
in selected patients despite initial toxicity, it becomes an 
attractive option in certain patient populations.
Tumor- associated B cells in melanoma are involved in 
drug resistance and retain a protumorigenic property 
in part through IGF-1 secretion.31 CD20 is also aber-
rantly expressed in subsets of melanoma cells with stem- 
cell properties.32 A pilot study showed median survival 
exceeding 1 year in patients with metastatic melanoma 
receiving rituximab.33 Reassuringly, a recent report 
showed that B- cell depletion or absence had no effect on 
tumor growth, response to PD-1 inhibition or survival.34
Several reports showed major predominant CD8 +T 
cells infiltrate in different series of ICI- related myocar-
ditis,35 36 hepatitis37 and acute interstitial nephritis 
(AIK).38 39 Recently, the analysis of BAL samples collected 
from patients with ICI- related pneumonitis showed 
increased BAL lymphocytosis, predominantly CD4 +T 
cells with central memory T cells with type I polarization 
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Figure 1 Flow chart for a suggested secondary prevention for ICI resumption after severe irAEs. For patients with no effective 
cancer treatment options and if there is no major contraindication related to a life- threatening irAEs, ICI could be resumed 
concomitantly with a prophylactic selective immunosuppressive therapy (SI). For severe ICI- related colitis, we advocate 
resuming ICI under VDZ, for severe ICI- related SS under anti- BAFF inhibitor±anti CD20 depletion, for severe ICI- related 
arthritis irAEs under TCZ, for ICI- related hemolytic anemia and thrombocytopenia irAEs under anti- CD20 depletion±IVIG. For 
ICI- related HES under anti- IL5(R), ICI- related pneumonitis under TCZ, ICI- related hepatitis under TCZ and ICI- related acute 
interstitial nephritis under TCZ. If patients experienced new or recurrent high- grade irAEs despite concomitant SI, we advocate 
the definitive ICI discontinuation and consideration of prompt local expertize for appropriate immunosuppressive treatment. 
VDZ 300 mg once every 2 months, belimumab (BLM) at 10 mg/kg every 4 weeks, TCZ 162 mg subcutaneously once per week 
or biweekly; or intravenously at 8 mg/kg once per month, RTX 500 mg to 1000 mg biweekly for 2 x, mepolizumab 300–750 mg 
monthly and benralizumab at 30 mg once monthly. BAFF, B- cell activating factor; HES, hypereosinophilic syndrome; IBD, 
inflammatory bowel disease; ICI, immune checkpoint inhibitor; IL-5, interleukin-5; irAEs, immune- related adverse events; IVIG, 
intravenous immunoglobulin; MAS, macrophage activation syndrome; PMR, polymyalgia rheumatica; RTX, rituximab; SS, 
Sjögren syndrome; TCZ, tocilizumab; VDZ, vedolizumab.
and decreased expression in BAL Tregs.40 Collectively, 
the data underline the essential and major role of T cells 
in the ICI- related toxicity.
Interleukin-6 (IL-6) is a major acute and chronic 
inflammatory phase mediator with protumorigenic prop-
erties.41 42 During inflammation, IL‐6 signaling drives T 
cell survival, expansion and proliferation.43 Intriguingly, 
blocking the IL-6 and PD-1/PD- L1 axes simultaneously 
provides synergistic antitumor effects on multiple levels, 
and the lack of IL-6 in the tumor microenvironment 
augments Th1 immunity and increases the efficacy of 
ICI.44–46 IL- 17A- expressing CD4+ T cells (c- Kit− CD161+ 
MDR1+ Th17 cells) have been found to be a major player 
of immune- related inflammation refractory to glucocorti-
coids.47 The pathogenic effect of IL-6 is indispensable in 
the differentiation of pro- inflammatory Th-17 cells from 
naïve CD4+ T cells, suggesting an implication for Th17 
subset in steroid- refractory irAEs.41 In contrast to other 
systemic immunosuppressive drugs (anti- TNF-α or nSI), 
blocking IL-6 is particularly interesting given this triple 
advantage without potentially compromising the efficacy 
of ICI. Similarly, it was also reported that interleukin-1β 
inhibition with canakinumab could significantly reduce 
incident lung cancer and lung cancer mortality.48
VDZ is a humanized monoclonal IgG1 antibody against 
α4β7 integrin that is approved for inflammatory bowel 
disease.49 50 α4β7 integrin is expressed on a subset of CD4 
+T cells that mediates homing of these cells specifically 
to the GI tract, hence allowing selective GI immunosup-
pression with VDZ51 while the immunity in extraintestinal 
tissues remains intact.52 In addition, VDZ does not bind to 
other integrins, such as α4β1, which is important for the 
homing of lymphocytes to a number of organs.52
Interestingly, it was reported that TNFα blockade over-
comes resistance to anti- PD-1 in experimental melanoma 
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because TNF blockade prevents anti- PD-1- induced 
TIL cell death as well as PD- L1 and TIM-3 expression. 
Furthermore, TNF expression positively correlates with 
expression of PD- L1 and TIM-3 in human melanoma 
specimens.53 More interestingly, prophylactic blockade 
of human TNF improved colitis and hepatitis in xeno-
grafted mice with human colon cancer and moreover, 
immunotherapeutic control of xenografted tumors was 
obtained.54
Collectively, given the reassuring safety profile of SI 
without compromising ICI effectiveness, resumption of 
ICI under secondary prevention with the most appropriate 
SI may have merit, in particularly if ICI is the only effec-
tive anticancer option. We recognize that ICI rechallenge 
may be considered in specific scenarios with very close 
follow- up after a very careful and thoughtful balance of 
risks and benefits in an individualized setting by a multispe-
cialty experienced team, taking into account a plethora of 
factors, as discussed above.
In general, we advocate for ICI- related colitis/enteritis 
to resume ICI under VDZ, SS- like irAEs under antiB- cell 
activating factor±anti- CD20 depletion55 56; inflammatory 
arthritis irAEs under TCZ19; hemolytic thrombocytopenia 
or anemia irAEs under anti- CD20 depletion±intrave-
nous immunoglobulin57; ICI- related hypereosinophilic 
syndrome under anti- IL5(R)58 59; ICI- related pneumonitis, 
hepatitis and AIK under TCZ (figure 1). If patients experi-
ence new or recurrent high- grade irAEs despite concom-
itant SI, we advocate definitive ICI discontinuation and 
consideration of prompt local expertize for appropriate 
treatment. Ideally, such strategies should be performed 
as part of well- designed prospective randomized trials or 
at least the data from these patients should be prospec-
tively collected into databases and registries for subsequent 
rigorous analyzes.
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